We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Wants More Postmarketing Studies of Seasonal Flu Vaccines
EMA Wants More Postmarketing Studies of Seasonal Flu Vaccines
Developers of seasonal flu vaccines for the EU market will need to conduct additional postmarket effectiveness studies and expand their criteria for evaluating immune responses to products in the clinical testing phase, a European Medicines Agency draft guideline says.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor